What it's for (Indications)
- Follitropin alfa is a recombinant human follicle-stimulating hormone (rFSH) indicated for various conditions related to infertility.
- In women, it is prescribed for the induction of ovulation and pregnancy in anovulatory infertile patients who have failed to respond to clomiphene citrate, provided primary ovarian failure is excluded.
- It is also indicated for controlled ovarian hyperstimulation (COH) to produce multiple follicles in ovulatory patients undergoing assisted reproductive technologies (ART) such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and gamete intrafallopian transfer (GIFT).
- In men, follitropin alfa, in conjunction with human chorionic gonadotropin (hCG) therapy, is indicated for the induction of spermatogenesis in men with hypogonadotropic hypogonadism for whom the cause of infertility is not primary testicular failure.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of follitropin alfa must be highly individualized and meticulously adjusted based on the patient's ovarian response, as assessed by ultrasonographic examination of ovarian follicular development and serial determinations of serum estradiol levels. For ovulation induction in anovulatory women, the typical starting dose is 50 to 75 International Units (IU) administered subcutaneously daily for the first 7 to 14 days. Subsequent dose adjustments, if needed, should not exceed 37.5 IU and should be made no more frequently than once every 7 days. For controlled ovarian hyperstimulation in women undergoing ART, an initial dose of 150 to 225 IU administered subcutaneously daily for the first 5 days is common, followed by individual adjustments based on response. In men for the induction of spermatogenesis, follitropin alfa is typically administered at a dose of 150 IU subcutaneously three times weekly, concurrently with hCG. Treatment duration can extend for several months, often for 3 to 6 months, or longer, to achieve adequate spermatogenesis. All administrations require careful medical supervision and monitoring. |
Safety & Warnings
Common Side Effects
- Common side effects associated with follitropin alfa treatment in women often include injection site reactions (such as pain, redness, bruising, or swelling), headache, abdominal pain or cramping, nausea, ovarian cysts, and breast tenderness.
- In men, common side effects may include injection site reactions, gynecomastia, acne, and weight gain.
- More serious adverse events, particularly in women, warrant close attention.
- These include Ovarian Hyperstimulation Syndrome (OHSS), a potentially life-threatening condition detailed further in the Warnings section.
- Other serious risks encompass multiple gestations (e.
- g.
- , twin or triplet pregnancies), which carry higher risks for both mother and fetuses, ectopic pregnancy, ovarian torsion, and thromboembolic events.
- Rarely, pulmonary and vascular complications, including acute respiratory distress syndrome, have been reported.
- Patients should be thoroughly counseled on all potential side effects and the importance of reporting any concerning symptoms promptly.
Serious Warnings
- Black Box Warning: Serious Warnings: Follitropin alfa does not carry a formal FDA Black Box Warning. However, healthcare providers and patients must be acutely aware of several serious risks associated with its use. The most critical of these is Ovarian Hyperstimulation Syndrome (OHSS), a potentially life-threatening medical condition characterized by severe ovarian enlargement, abdominal distention, ascites, pleural effusion, electrolyte imbalances, hemoconcentration, and increased risk of thromboembolic events (e.g., pulmonary embolism, stroke, myocardial infarction). Close monitoring of ovarian response and serum estradiol levels is paramount to minimize the risk of OHSS. Another significant risk is the increased incidence of multiple gestations (e.g., twin, triplet, or higher-order pregnancies), which are associated with substantially higher maternal and fetal morbidity and mortality compared to singleton pregnancies. Patients must be thoroughly counseled on these risks before commencing treatment. Other serious complications include ectopic pregnancy and ovarian torsion. Vigilant monitoring and patient education are essential components of safe and effective follitropin alfa therapy.
- Serious Warnings: Follitropin alfa treatment carries several significant risks that necessitate careful patient selection, meticulous monitoring, and thorough patient counseling.
- The most critical concerns include Ovarian Hyperstimulation Syndrome (OHSS), a potentially life-threatening medical condition characterized by severe ovarian enlargement, ascites, dyspnea, and an increased risk of thromboembolic events, including pulmonary embolism.
- Patients should be closely monitored for signs and symptoms of OHSS, and treatment parameters may need to be adjusted or withheld.
- Furthermore, there is a significantly increased risk of multiple gestations, which is associated with higher maternal and fetal morbidity and mortality.
- Patients must be fully informed of these risks before initiating therapy.
- Ectopic pregnancy and ovarian torsion are also recognized serious complications.
- Counseling regarding the potential for serious complications and the importance of adherence to monitoring schedules is paramount to optimize safety and outcomes.
- Additional warnings include an increased risk of thromboembolic events, particularly in patients with a personal or family history of thrombophlebitis, severe obesity, or thrombophilia.
- Pulmonary and vascular complications, such as acute respiratory distress syndrome, can occur.
- While a causal relationship has not been definitively established, ovarian tumors (benign and malignant) have been reported in women undergoing multiple drug regimens for infertility treatment, and patients should be advised of this potential risk.
- The incidence of congenital malformations after ART may be slightly increased compared to spontaneous conceptions, though this is often attributed to the underlying infertility and ART procedures rather than follitropin alfa itself.
How it Works (Mechanism of Action)
Follitropin alfa is a highly purified preparation of recombinant human follicle-stimulating hormone (rFSH), a glycoprotein hormone crucial for reproduction. Its primary mechanism of action involves binding to specific FSH receptors located on the granulosa cells within the ovarian follicles in females and on the Sertoli cells in the seminiferous tubules of the testes in males. In women, FSH stimulates the growth and development of ovarian follicles, promoting follicular maturation and estradiol synthesis. It facilitates the conversion of androgens to estrogens within the follicle, crucial for follicular development and endometrial proliferation. In conjunction with luteinizing hormone (LH) or human chorionic gonadotropin (hCG), FSH supports the final maturation of the oocyte and ovulation. In men, FSH, alongside LH and testosterone, is essential for stimulating and maintaining spermatogenesis, promoting the proliferation and differentiation of germ cells within the testes.
Commercial Brands (Alternatives)
No other brands found for this formula.